Research progress of recombinant novel coronavirus protein vaccine

Abstract

The coronavirus situation is dire around the world, with more than 594 million confirmed infections and nearly 6.45 million deaths. It was found that SARS-CoV-2 and SARS-CoV have a high level of genomic similarity (peak glycoprotein serial similarity of 87.2%) , which provide a basis for vaccine development. In the context of the 2022 novel coronavirus pandemic, there is an urgent need for a vaccine that can effectively protect against the virus that must be relatively safe while being effective and predictable as well. We found that recombinant protein vaccines seem to be able to effectively solve most of the current problems after comparing several existing vaccines. This literature review mainly introduces its overall background and the development steps of this technology, including how to screen for pathogenic proteins, how to implant in CHO cells and culture after infusion, and how to isolate and purify mature spike proteins that have been cultured. And supplemented with animal clinical trials of vaccines and ACE2 receptors and prospects for the future.